As of June 15, 2020, Tocagen Inc. was acquired by Forte Biosciences, Inc., in a reverse merger transaction.
+ 1 more risk
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has Tocagen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TOCA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: TOCA underperformed the US Biotechs industry which returned 16.5% over the past year.
Return vs Market: TOCA underperformed the US Market which returned 5% over the past year.
Price Volatility Vs. Market
How volatile is Tocagen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall StWhat Percentage Of Tocagen Inc. (NASDAQ:TOCA) Shares Do Insiders Own?
5 months ago | Simply Wall StIntroducing Tocagen (NASDAQ:TOCA), The Stock That Tanked 94%
10 months ago | Simply Wall StHow Many Tocagen Inc. (NASDAQ:TOCA) Shares Did Insiders Buy, In The Last Year?
Is Tocagen undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TOCA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TOCA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TOCA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: TOCA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TOCA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TOCA is overvalued based on its PB Ratio (14.5x) compared to the US Biotechs industry average (3.5x).
How is Tocagen forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tocagen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of TOCA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Tocagen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TOCA is currently unprofitable.
Growing Profit Margin: TOCA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TOCA is unprofitable, and losses have increased over the past 5 years at a rate of -24.1% per year.
Accelerating Growth: Unable to compare TOCA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TOCA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: TOCA has a negative Return on Equity (-2723.92%), as it is currently unprofitable.
How is Tocagen's financial position?
Financial Position Analysis
Short Term Liabilities: TOCA's short term assets ($14.5M) exceed its short term liabilities ($12.6M).
Long Term Liabilities: TOCA's short term assets ($14.5M) exceed its long term liabilities ($3.9M).
Debt to Equity History and Analysis
Debt Level: TOCA's debt to equity ratio (239.2%) is considered high.
Reducing Debt: Insufficient data to determine if TOCA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TOCA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TOCA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23.5% each year
What is Tocagen's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TOCA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TOCA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TOCA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TOCA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TOCA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Tocagen has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TOCA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Tocagen Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Tocagen Inc.
- Ticker: TOCA
- Exchange: NasdaqGS
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$30.138m
- Shares outstanding: 23.92m
- Website: https://www.tocagen.com
Number of Employees
- Tocagen Inc.
- 4242 Campus Point Court
- Suite 500
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TOCA||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Apr 2017|
|37T||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Apr 2017|
As of June 15, 2020, Tocagen Inc. was acquired by Forte Biosciences, Inc., in a reverse merger transaction. Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company’s lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/16 09:25|
|End of Day Share Price||2020/06/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.